Thrombogenic potential of innovia polymer valves versus Carpentier-Edwards Perimount Magna Sortic Bioprosthetic Balves

ASAIO Journal

Volumn 57, Issue 1, 2011, Pages 26-31

  Claiborne, Thomas E ^a   Girdhar, Gaurav ^a   Gallocher Lowe, Siobhain ^b   Sheriff, Jawaad ^a   Kato, Yasushi P ^c   Pinchuk, Leonard ^c   Schoephoerster, Richard T ^d   Jesty, Jolyon ^e   Bluestein, Danny ^a  

^a St Francis Hospital The Heart Center   (United States)

^b Florida International University   (United States)

^c Innovia LLC   (United States)

^d 500 W University Avenue   (United States)

^e STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AORTIC VALVES; FURTHER DEVELOPMENT; IN-VITRO; LEFT VENTRICULAR ASSIST DEVICES; MECHANICAL CIRCULATORY SUPPORT; PLATELET ACTIVATION; PROTHROMBINASE; TRANSCATHETER; VALVE DESIGN;

BIOMINERALIZATION; BLOOD VESSELS; BUTENES; FLOW CYTOMETRY; HEART VALVE PROSTHESES; HYDRODYNAMICS; PLATELETS; POLYMERS; STYRENE;

VALVES (MECHANICAL);

POLY(STYRENE B ISOBUTYLENE B STYRENE); POLY(STYRENE-B-ISOBUTYLENE-B-STYRENE); POLYMER; STYRENE DERIVATIVE;

AORTA VALVE; ARTICLE; BIOPROSTHESIS; COMPARATIVE STUDY; EVALUATION; HEART ASSIST DEVICE; HEART VALVE PROSTHESIS; HEMODYNAMICS; HUMAN; IN VITRO STUDY; PROSTHESIS; THROMBOCYTE ACTIVATION; THROMBOSIS;

AORTIC VALVE; BIOPROSTHESIS; HEART VALVE PROSTHESIS; HEART-ASSIST DEVICES; HEMODYNAMICS; HUMANS; PLATELET ACTIVATION; POLYMERS; PROSTHESIS DESIGN; STYRENES; THROMBOSIS;

EID: 78751566512     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAT.0b013e3181fcbd86     Document Type: Article

References (36)

1. Rosamond W, Flegal K, Friday C, et al: Heart disease and stroke statistics-2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115: e69-e171, 2007.
2. Edmunds LH Jr, McKinlay S, Anderson JM, et al: Directions for improvement of substitute heart valves: National Heart, Lung, and Blood Institute's Working Croup report on heart valves. J Biomed Mater Res 38: 263-266, 1997.
3. Bonow RO, Carabello BA, Chatterjee K, et al: 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Cuidelines (Writing Committee to Revise the 1998 Cuidelines for the Management of Patients with Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 118: e523-e661, 2008.
4. Cannegieter SC, Rosendaal FR, Wintzen AR, et al: Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333: 11-17, 1995.
5. Kulik A, Bédard P, Lam BK, et al: Mechanical versus bioprosthetic valve replacement in middle-aged patients. Eur J Cardiothorac Surg 30: 485-491, 2006.
6. Senthilnathan V, Treasure T, Crunkemeier C, Starr A: Heart valves: Which is the best choice? Cardiovasc Surg 7: 393-397, 1999.
7. Cao C, Wu Y, Crunkemeier CL, et al: Durability of pericardial versus porcine aortic valves. J Am Coll Cardiol 44: 384-388, 2004.
8. Chanbari H, Viatge H, Kidane AC, et al: Polymeric heart valves: New materials, emerging hopes. Trends Biotechnol 27: 359-367, 2009.
9. Hyde JA, Chinn JA, Phillips RE Jr: Polymer heart valves. J Heart Valve Dis 8: 331-339, 1999.
10. Callocher SL, Aguirre AF, Kasyanov V, et al: A novel polymer for potential use in a trileaflet heart valve. J Biomed Mater Res B Appl Biomater 79: 325-334, 2006.
11. Pinchuk L, Wilson CJ, Barry JJ, et al: Medical applications of poly(styrene-block-isobutylene-block-styrene) ("SIBS"). Biomaterials 29: 448-460, 2008.
12. Strickler F, Richard R, McFadden S, et al: In vivo and in vitro characterization of poly(styrene-b-isobutylene-b-styrene) copolymer stent coatings for biostability, vascular compatibility and mechanical integrity. J Biomed Mater Res A 92: 773-782, 2010.
13. Boden M, Richard R, Schwarz MC, et al: In vitro and in vivo evaluation of the safety and stability of the TAXUS Paclitaxel-Eluting Coronary Stent. J Mater Sci Mater Med 20: 1553-1562, 2009.
14. Yin W, Callocher S, Pinchuk L, et al: Flow-induced platelet activation in a St. Jude mechanical heart valve, a trileaflet polymeric heart valve, and a St. Jude tissue valve. Artif Organs 29: 826-831, 2005.
15. Gallocher S: Durability Assessment of Polymer Trileaflet Heart Valves, PhD Thesis. Miami, Biomedical Engineering, Florida International University; 2007.
16. Duraiswamy N, Choksi TD, Pinchuk L, Schoephoerster RT: A phospholipid-modified polystyrene-polyisobutylene-polystyrene (SIBS) triblock polymer for enhanced hemocompatibility and potential use in artificial heart valves. J Biomater Appl 23: 367-379, 2009.
17. Wang Q, McGoron AJ, Pinchuk L, Schoephoerster RT: A novel small animal model for biocompatibility assessment of polymeric materials for use in prosthetic heart valves. J Biomed Mater Res A 93: 442-453, 2010.
18. Claiborne TE, Bluestein D, Schoephoerster RT: Development and evaluation of a novel artificial catheter-deliverable prosthetic heart valve and method for in vitro testing. Int J Artif Organs 32: 262-271, 2009.
19. Kereiakes DJ, Michelson AD: Platelet activation and progression to complications. Rev Cardiovasc Med 7: 75-81, 2006.
20. Bluestein D, Chandran KB, Manning KB: Towards non-thrombogenic performance of blood recirculating devices. Ann Biomed Eng 38: 1236-1256, 2010.
21. Schulz-Heik K, Ramachandran J, Bluestein D, Jesty J: The extent of platelet activation under shear depends on platelet count: Differential expression of anionic phospholipid and factor Va. Pathophysiol Haemost Thromb 34: 255-262, 2005.
22. Yin W, Alemu Y, Affeld K, et al: Flow-induced platelet activation in bileaflet and monoleaflet mechanical heart valves. Ann Biomed Eng 32: 1058-1066, 2004.
23. Jesty J, Bluestein D: Acetylated prothrombin as a substrate in the measurement of the procoagulant activity of platelets: Elimination of the feedback activation of platelets by thrombin. Anal Biochem 272: 64-70, 1999.
24. Bluestein D, Yin W, Affeld K, Jesty J: Flow-induced platelet activation in mechanical heart valves. J Heart Valve Dis 13: 501-508, 2004.
25. Girdhar G, Xu S, Bluestein D, Jesty J: Reduced-nicotine cigarettes increase platelet activation in smokers in vivo: A dilemma in harm reduction. Nicotine Tob Res 10: 1 73 7-1744, 2008.
26. Bonow RO, Carabello BA, Kanu C, et al: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Developed in collaboration with the Society of Cardiovascular Anesthesiologists: Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114: e84-e231, 2006.
27. Leverett LB, Hellums JD, Alfrey CP, Lynch EC: Red blood cell damage by shear stress. Biophys J 12: 257-273, 1972.
28. Nobili M, Sheriff J, Morbiducci U, et al: Platelet activation due to hemodynamic shear stresses: Damage accumulation model and comparison to in vitro measurements. ASAIO J 54: 64-72, 2008.
29. Brown CH 3rd, Lemuth RF, Hellums JD, et al: Response of human platelets to sheer stress. Trans Am Soc Artif Intern Organs 21: 35-39, 1975.
30. Avrahami I, Rosenfeld M, Einav S: The hemodynamics of the Berlin pulsatile VAD and the role of its MHV configuration. Ann Biomed Eng 34: 13 73-1388, 2006.
31. Hagberg IA, Lyberg T: Blood platelet activation evaluated by flow cytometry: Optimised methods for clinical studies. Platelets 11: 137-150, 2000.
32. Rubenstein DA, Yin W: Glycated albumin modulates platelet susceptibility to flow induced activation and aggregation. Plate-lets 20: 206-215, 2009.
33. Dalmau MJ, Maríagonzález-Santos J, Lopez-Rodriguez J, et al: The Carpentier-Edwards Perimount Magna aortic xenograft: A new design with an improved hemodynamic performance. Interact Cardiovasc Thorac Surg 5: 263-267, 2006.
34. Borger MA, Nette AF, Maganti M, Feindel CM: Carpentier-Edwards Perimount Magna valve versus Medtronic Hancock II: A matched hemodynamic comparison. Ann Thorac Surg 83: 2054-2058, 2007.
35. Xenos M, Girdhar G, Alemu Y, et al: Device Thrombogenicity Emulator (DTE)-Design optimization methodology for cardiovascular devices: A study in two bileaflet MHV designs. J Biomech 43: 2400-2409, 2010.
36. Alemu Y, Girdhar G, Xenos M, et al: Design optimization of a mechanical heart valve for reducing valve thrombogenicity - A case study with ATS valve. ASAIO J 56: 389-396, 2010.